Department of Neurosurgery, Massachusetts General Hospital, Boston, MA, USA.

1. Combination Therapy of Adagrasib and Abemaciclib in NSCLC Brain Metastasis (KRAS-G12C, CDKN2A loss)

• Neurosurgery relevance: 'High'. Targets brain metastases; neurosurgeons must consider systemic options that affect surgical decisions.
• Oncology relevance: 'Very high'. KRAS-G12C is a hot target; combination with CDK4/6 inhibition is cutting-edge.
• Clinical impact: Personalization of therapy may delay or reduce the need for surgery or radiosurgery.

• Neurosurgery relevance: 'Very high'. Glioblastoma is a core concern in neurosurgical oncology; virotherapy may be integrated intraoperatively.
• Oncology relevance: 'High'. Combines gene therapy and immunotherapy approaches in neuro-oncology.
• Clinical impact: Preclinical but promising as adjunct to surgical resection.